Cargando…
Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
Limited data are available regarding optimal treatment for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We evaluated outcomes of inhaled amikacin (AMK) with clofazimine (CFZ) regimens as an add-on salvage therapy for refractory MAC-PD. We retrospectively analyzed 52 patients wi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565500/ https://www.ncbi.nlm.nih.gov/pubmed/32937940 http://dx.doi.org/10.3390/jcm9092968 |
_version_ | 1783595946649583616 |
---|---|
author | Kim, Bo-Guen Kim, Hojoong Kwon, O. Jung Huh, Hee Jae Lee, Nam Yong Baek, Sun-Young Sohn, Insuk Jhun, Byung Woo |
author_facet | Kim, Bo-Guen Kim, Hojoong Kwon, O. Jung Huh, Hee Jae Lee, Nam Yong Baek, Sun-Young Sohn, Insuk Jhun, Byung Woo |
author_sort | Kim, Bo-Guen |
collection | PubMed |
description | Limited data are available regarding optimal treatment for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We evaluated outcomes of inhaled amikacin (AMK) with clofazimine (CFZ) regimens as an add-on salvage therapy for refractory MAC-PD. We retrospectively analyzed 52 patients with refractory MAC-PD, characterized by persistently positive sputum cultures despite >6 months of treatment. Thirty-five (67%) patients had M. intracellulare-PD, and 17 (33%) patients had M. avium-PD. Twenty-seven (52%) patients received the salvage therapy for ≥12 months, whereas 25 (48%) patients were treated for <12 months due to adverse effects or other reasons. Seventeen (33%) patients had culture conversion: 10 (10/27) in the ≥12-month treatment group and seven (7/25) in the <12-month treatment group (p = 0.488). Microbiological cure, defined as maintenance of culture negativity, was achieved in 12 (23%) patients; six (6/12) with accompanying symptomatic improvement were considered to have reached cure. Clinical cure, defined as symptomatic improvement with <3 consecutive negative cultures, was achieved in three (6%) patients. Overall, 15 (29%) patients achieved favorable outcomes, including microbiological cure, cure, and clinical cure. Inhaled AMK with CFZ may provide favorable outcomes in some patients with refractory MAC-PD. However, given the adverse effects, more effective strategies are needed to maintain these therapeutic regimens. |
format | Online Article Text |
id | pubmed-7565500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75655002020-10-26 Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease Kim, Bo-Guen Kim, Hojoong Kwon, O. Jung Huh, Hee Jae Lee, Nam Yong Baek, Sun-Young Sohn, Insuk Jhun, Byung Woo J Clin Med Article Limited data are available regarding optimal treatment for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We evaluated outcomes of inhaled amikacin (AMK) with clofazimine (CFZ) regimens as an add-on salvage therapy for refractory MAC-PD. We retrospectively analyzed 52 patients with refractory MAC-PD, characterized by persistently positive sputum cultures despite >6 months of treatment. Thirty-five (67%) patients had M. intracellulare-PD, and 17 (33%) patients had M. avium-PD. Twenty-seven (52%) patients received the salvage therapy for ≥12 months, whereas 25 (48%) patients were treated for <12 months due to adverse effects or other reasons. Seventeen (33%) patients had culture conversion: 10 (10/27) in the ≥12-month treatment group and seven (7/25) in the <12-month treatment group (p = 0.488). Microbiological cure, defined as maintenance of culture negativity, was achieved in 12 (23%) patients; six (6/12) with accompanying symptomatic improvement were considered to have reached cure. Clinical cure, defined as symptomatic improvement with <3 consecutive negative cultures, was achieved in three (6%) patients. Overall, 15 (29%) patients achieved favorable outcomes, including microbiological cure, cure, and clinical cure. Inhaled AMK with CFZ may provide favorable outcomes in some patients with refractory MAC-PD. However, given the adverse effects, more effective strategies are needed to maintain these therapeutic regimens. MDPI 2020-09-14 /pmc/articles/PMC7565500/ /pubmed/32937940 http://dx.doi.org/10.3390/jcm9092968 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Bo-Guen Kim, Hojoong Kwon, O. Jung Huh, Hee Jae Lee, Nam Yong Baek, Sun-Young Sohn, Insuk Jhun, Byung Woo Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title | Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title_full | Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title_fullStr | Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title_full_unstemmed | Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title_short | Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease |
title_sort | outcomes of inhaled amikacin and clofazimine-containing regimens for treatment of refractory mycobacterium avium complex pulmonary disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565500/ https://www.ncbi.nlm.nih.gov/pubmed/32937940 http://dx.doi.org/10.3390/jcm9092968 |
work_keys_str_mv | AT kimboguen outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT kimhojoong outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT kwonojung outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT huhheejae outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT leenamyong outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT baeksunyoung outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT sohninsuk outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease AT jhunbyungwoo outcomesofinhaledamikacinandclofaziminecontainingregimensfortreatmentofrefractorymycobacteriumaviumcomplexpulmonarydisease |